

European Society for Medical Oncology (ESMO) Congress 2025
October 17-21, 2025
Berlin, Germany
Abstracts

CCTG CO.29 - Circulating Tumor DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colon Cancer: A Multicentre Phase II/III Randomised Controlled Study (DYNAMIC III)

Session Type: Oral Session presented as part of the Presidential Symposium

Session Title: Presidential Symposium III

Abstract #: LBA9

Abstract: ***CO.29 ctDNA-guided adjuvant chemotherapy de-escalation in stage III colon cancer: Primary analysis of the ctDNA-negative cohort from the randomized AGITG DYNAMIC-III trial (Intergroup study of AGITG and CCTG).***

Authors: Jeanne Tie (Australia), Yuxuan Wang (US), Jonathan M. Loree (Canada), Joshua Cohen (US), David Espinoza (Australia), Rachel Wong (Australia), Timothy J. Price (Australia), Niall Tebbutt (Australia), Matthew Burge (Australia), James Lynam (Australia), Belinda Lee (Australia), Samuel J. Harris (Australia), Lorraine Chantrill (Australia), Daniel A. Breadner (Canada), Christopher O'Callaghan (Canada), Chetan Bettegowda (US), Nicholas Papadopoulos (US), Kenneth Kinzler (US), Bert Vogelstein (US), Peter Gibbs (Australia)

Website Link: <https://cslide.ctimeetingtech.com/esmo2025/attendee/confcal/session/list?q=LBA9>

CCTG CO.21 - A Phase III Study of the Impact of a Physical Activity Program on Disease-Free Survival in Patients with High Risk Stage II or Stage III Colon Cancer: A Randomized Controlled Trial (CHALLENGE).

Session Type: Mini Oral Session

Session Title: Mini oral session: GI tumours, lower digestive

Abstract #: LBA28

Abstract: ***Predictors of adherence to the structured exercise program and physical activity target in the Canadian Cancer Trials Group CO.21 CHALLENGE trial.***

Authors: Christopher M. Booth (Canada), Janette Vardy (Australia), Christopher O'Callaghan (Canada), Sharlene Gill (Canada), Rebecca K. Wong (Canada), Haryana Dhillon (Australia), Christine Friendenreich (Canada), Victoria Coyle (United Kingdom), Neil Chua (Canada), Derek Jonker (Canada), Shahid Ahmed (Canada), Anthony Reiman (Canada), Kristin Campbell (Canada), Fernanda Arthuso (Canada), John R. Zalcborg (Australia), Stephen Clarke (Australia), Stephen Begbie (Australia), Patti O'Brien (Canada), Dongsheng Tu (Canada), Kerry Courneya (Canada)

Website Link: <https://cslide.ctimeetingtech.com/esmo2025/attendee/confcal/session/list?q=LBA28>

CCTG PA.7 - A Randomized Phase II Trial of Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma

Session Type: Posters

Session Title: ePosters

Abstract #: 2249P

Citation: Volume 36, Supplement 2S1246, September 2025

Abstract: *Baseline methylthioadenosine (MTA) levels as potential prognostic markers in metastatic pancreatic ductal adenocarcinoma (mPDAC): An exploratory analysis of CCTG PA.7 trial*

Authors: Harry M. Harvey (Ireland), Emma Titmuss (Canada), James Topham (Canada), Daniel J. Renouf (Canada), Jennifer Knox (Canada), Petr Kavan (Canada), Derek Jonker (Canada), Stephen A. Welch (Canada), Felix Couture (Canada), Frederic Lemay (Canada), Mustapha Tehfe (Canada), Mohammed Harb (Canada), Nathalie Aucoin (Canada), Yoo-Joung Ko (Canada), Patricia Tang (Canada), Ravi Ramjeesingh (Canada), Brandon Meyers (Canada), Christopher O'Callaghan (Canada), Jonathan M. Loree (Canada) Eric Chen (Canada)

Website Link: [https://www.annalsofoncology.org/article/S0923-7534\(25\)03786-X/fulltext](https://www.annalsofoncology.org/article/S0923-7534(25)03786-X/fulltext)

Session Type: Posters

Session Title: ePosters

Abstract #: 2457P

Citation: Volume 36, Supplement 2S1333-S1334 September 2025

Abstract: *CDK12 as a prostate cancer predisposition gene*

Authors: Sofie H. Tolmeijer (Canada), Corinne Maurice-Dror (Canada), Claire M. De la Calle (United States of America), Mohamed Adil (United States of America), Nielka Van Erp (Netherlands), Shahneen K. Sandhu (Australia), Michael S. Hofman (Australia), Andre M. Bergman (Netherlands), Lesley K. Seymour (Canada), Peter C. Black (Canada), Peter Nelson (United States of America), Elena Castro Marcos (Spain), Kasmintan A. Schrader (Canada), Gavin Ha (United States of America), Heather H. Cheng (United States of America), Piet Ost (Belgium), David Olmos (Spain), Kim Nguyen Chi (Canada), Colin C. Pritchard (United States of America), Alexander W. Wyatt (Canada)

Website Link: <https://www.annalsofoncology.org/article/S0923-7534%2825%2903992-4/fulltext>

CCTG BR.31 - A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Cancer

Session Type: Mini Oral

Session Title: Mini oral session 2: Non-metastatic NSCLC

Abstract #: LBA68

Abstract: *CCTG BR.31: Adjuvant durvalumab (D) in resected non-small-cell lung cancer (NSCLC): Final overall survival (OS) and minimal residual disease (MRD) analyses.*

Authors: Glenwood Goss (Canada), Gail Darling (Canada), Virginie Westeel (France), Kazuhiko Nakagawa (Japan), Bartomeu Massuti Sureda (Spain), Francesco Perrone (Italy), Sue-Anne McLachlan (Australia), Jin H. Kang (Republic of Korea), Yi-Long Wu (China), Anne-Marie C. Dingemans (Netherlands), Rafal Dziadziuszko (Poland), Morihito Okada (Japan), Laurent Greillier (France), Clarisse Audigier-Valette (France), Shunichi Sugawara (Japan), Ernest Nadal (Spain), Annamaria Catino (Italy), Martin R. Stockler (Australia), Keyue U. Ding (Canada), Christopher O'Callaghan (Canada)

Website Link: <https://cslide.ctimeetingtech.com/esmo2025/attendee/confcal/session/list?q=LBA68>

CCTG PR.21 - A Randomized Phase II Study of 177Lu-PSMA-617 vs Docetaxel in Patients with Metastatic Castration-Resistant Prostate Cancer and PSMA-Positive Disease

Session Type: Oral proffered paper session

Session Title: Proffered Paper session: Radioligand therapeutics

Abstract #: LBA89

Abstract: *A randomized phase II study of 177Lu-PSMA-617 vs docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) and PSMA-positive disease: Canadian Cancer Trials Group (CCTG) study PR.21.*

Authors: Kim Nguyen Chi (Canada), Fred Saad (Canada), Keyue U. Ding (Canada), Glenn Bauman (Canada), Urban Emmenegger (Canada), Sebastien J. Hotte (Canada), Frederic Pouliot (Canada), Justin Lee (Canada), Jean-Mathieu Beaugregard (Canada), Lucia Nappi (Canada), Christian K. Kollmannsberger (Canada), Zineb Hamilou (Canada), Gad Abikhzer (Canada), Michel Pavic (Canada), Scott North (Canada), Di Maria Jiang (Canada), Steven M. Yip (Canada), Conor Dellar (Canada), Wendy R. Parulekar (Canada), Francois Benard (Canada)

Website Link: <https://cslide.ctimeetingtech.com/esmo2025/attendee/confcal/session/list?q=LBA89>

CCTG MAC.18 (ALLIANCE A221405) - POSITIVE: A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women with Endocrine Responsive Breast Cancer who Desire Pregnancy

Session Type: Proffered Paper session

Session Title: Proffered Paper session: Breast cancer, early stage

Abstract #: LBA12

Abstract: *5-year follow-up results from the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) trial*

Authors: Fedro A. Peccatori (Italy), Olivia Pagani (Switzerland), Samuel M. Niman (US), Monica Ruggeri (Switzerland), Hatem A. Azim (Egypt), Marco A. Colleoni (Italy), Cristina Saura Manich (Spain), Chikako Shimizu (Japan), Anna Satersdal (Norway), Judith R. Kroep (Netherlands), Ellen Warner (Canada), Audrey Mailliez (France), Frederic Amant (Belgium), Teresa Ferreiro (Spain), Martine Piccart (Belgium), Larissa A. Korde (US), Aron Goldhirsch (Italy), Richard D. Gelber (US), Ann H. Partridge (US)

Website Link: <https://cslide.ctimeetingtech.com/esmo2025/attendee/confcal/session/list?q=LBA12>
